{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:38:29Z","timestamp":1792643909299,"version":"4.5.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.mayocp.2026.05.009","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T23:32:31Z","timestamp":1779838351000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Lupus Erythematosus: What Every Clinician Needs to Know"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1749-5719","authenticated-orcid":false,"given":"Al\u00ed","family":"Duarte-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ardekani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun W.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000614","article-title":"Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries","volume":"8","author":"Izmirly","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.05.009_bib2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.41632","article-title":"Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries","volume":"73","author":"Izmirly","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.05.009_bib3","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/annrheumdis-2022-222276","article-title":"Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades","volume":"81","author":"Duarte-Garc\u00eda","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.mayocp.2026.05.009_bib4","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1002\/art.40191","article-title":"The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California: the California Lupus Surveillance Project","volume":"69","author":"Dall'Era","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.05.009_bib5","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/art.40192","article-title":"The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: the Manhattan Lupus Surveillance Program","volume":"69","author":"Izmirly","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.05.009_bib6","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/art.38720","article-title":"Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009","volume":"66","author":"Ferucci","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.009_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/art.38239","article-title":"The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia Lupus Registry","volume":"66","author":"Lim","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.009_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.38238","article-title":"Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance Program","volume":"66","author":"Somers","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.05.009_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.05.009_bib10","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1136\/annrheumdis-2017-211663","article-title":"Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016","volume":"76","author":"Tektonidou","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/acr.22173","article-title":"Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies","volume":"66","author":"Yurkovich","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"10.1016\/j.mayocp.2026.05.009_bib12","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3899\/jrheum.080214","article-title":"Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus","volume":"35","author":"Urowitz","year":"2008","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.009_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/rheumatology\/kex412","article-title":"Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014)","volume":"57","author":"Jorge","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.mayocp.2026.05.009_bib14","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/art.40512","article-title":"Brief report: lupus \u2014 an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015","volume":"70","author":"Yen","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.05.009_bib15","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/rheumatology\/kead617","article-title":"Multimorbidity in systemic lupus erythematosus in a population-based cohort: the Lupus Midwest Network","volume":"63","author":"Figueroa-Parra","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.mayocp.2026.05.009_bib16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/art.39070","article-title":"Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis","volume":"67","author":"Feldman","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.05.009_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.4088\/JCP.11r07425","article-title":"Psychiatric symptoms in systemic lupus erythematosus: a systematic review","volume":"73","author":"Meszaros","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.mayocp.2026.05.009_bib18","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1093\/rheumatology\/keab855","article-title":"Work participation in patients with systematic lupus erythematosus: a systematic review","volume":"61","author":"Blomjous","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.mayocp.2026.05.009_bib19","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.1780350310","article-title":"A revised estimate of twin concordance in systemic lupus erythematosus","volume":"35","author":"Deapen","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.mayocp.2026.05.009_bib21","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/ng.3434","article-title":"Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus","volume":"47","author":"Bentham","year":"2015","journal-title":"Nat Genet"},{"issue":"824","key":"10.1016\/j.mayocp.2026.05.009_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ady0210","article-title":"Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus","volume":"17","author":"Younis","year":"2025","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/art.20049","article-title":"Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis","volume":"50","author":"Costenbader","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.mayocp.2026.05.009_bib24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/acr.24974","article-title":"Association of ultraviolet B radiation and risk of systemic lupus erythematosus among women in the Nurses' Health Studies","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.mayocp.2026.05.009_bib25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1196\/annals.1422.019","article-title":"Drug-induced lupus","volume":"1108","author":"Borchers","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.1016\/j.mayocp.2026.05.009_bib26","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1002\/art.23701","article-title":"Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome","volume":"58","author":"Scofield","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.mayocp.2026.05.009_bib27","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.39560","article-title":"X chromosome dose and sex bias in autoimmune diseases: increased prevalence of 47,XXX in systemic lupus erythematosus and Sjogren's syndrome","volume":"68","author":"Liu","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.009_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/annrheumdis-2021-220793","article-title":"Human SLE variant NCF1-R90H promotes kidney damage and murine lupus through enhanced Tfh2 responses induced by defective efferocytosis of macrophages","volume":"81","author":"Geng","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.mayocp.2026.05.009_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri.2017.24","article-title":"Altered B cell signalling in autoimmunity","volume":"17","author":"Rawlings","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.009_bib30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.kint.2024.10.018","article-title":"Lupus nephritis: redefining the treatment goals","volume":"107","author":"De Vriese","year":"2025","journal-title":"Kidney Int"},{"issue":"1S","key":"10.1016\/j.mayocp.2026.05.009_bib31","first-page":"S1","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.mayocp.2026.05.009_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.05.009_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/jir.2011.0045","article-title":"Type I interferon and systemic lupus erythematosus","volume":"31","author":"Elkon","year":"2011","journal-title":"J Interferon Cytokine Res"},{"issue":"7","key":"10.1016\/j.mayocp.2026.05.009_bib34","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ndt\/gfae294","article-title":"Optimal glucocorticoid therapy in lupus nephritis","volume":"40","author":"Figueroa-Parra","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.mayocp.2026.05.009_bib35","article-title":"2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus","author":"Sammaritano","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.mayocp.2026.05.009_bib36","article-title":"2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9767","key":"10.1016\/j.mayocp.2026.05.009_bib39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib41","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/acr.25445","article-title":"Clinical presentation, care pathways, and delays in access to specialized care in patients with systemic lupus erythematosus: a study from Lupus Midwest Network (LUMEN)","volume":"77","author":"Sanchez-Rodriguez","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.mayocp.2026.05.009_bib43","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.05.009_bib44","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/ard.2009.117200","article-title":"European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies","volume":"69","author":"Mosca","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.mayocp.2026.05.009_bib45","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.05.009_bib46","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/acr.25528","article-title":"2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.mayocp.2026.05.009_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1874312901409010082","article-title":"Applying Choosing Wisely: Antinuclear Antibody (ANA) and Sub-Serology Testing in a Safety Net Hospital System","volume":"9","author":"Davis","year":"2015","journal-title":"Open Rheumatol J"},{"issue":"12","key":"10.1016\/j.mayocp.2026.05.009_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102400","article-title":"ANA as an entry criterion for the classification of SLE","volume":"18","author":"Pisetsky","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib49","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/acr.23292","article-title":"Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data","volume":"70","author":"Leuchten","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.mayocp.2026.05.009_bib50","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/art.34380","article-title":"Prevalence and sociodemographic correlates of antinuclear antibodies in the United States","volume":"64","author":"Satoh","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.mayocp.2026.05.009_bib51","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.1780400909","article-title":"Range of antinuclear antibodies in \"healthy\" individuals","volume":"40","author":"Tan","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.mayocp.2026.05.009_bib52","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41584-020-00522-w","article-title":"Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases","volume":"16","author":"Bossuyt","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.05.009_bib53","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1016\/S2665-9913(20)30084-9","article-title":"Utility of repeated antinuclear antibody tests: a retrospective database study","volume":"2","author":"Yeo","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.mayocp.2026.05.009_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102615","article-title":"Clinical disease activity and flare in SLE: Current concepts and novel biomarkers","volume":"119","author":"Thanou","year":"2021","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.31138\/mjr.28.1.4","article-title":"Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies","volume":"28","author":"Adamichou","year":"2017","journal-title":"Mediterr J Rheumatol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.05.009_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031850","article-title":"Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"10","author":"Murimi-Worstell","year":"2020","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.mayocp.2026.05.009_bib57","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.autrev.2016.02.019","article-title":"Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review","volume":"15","author":"Floris","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.009_bib59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1191\/096120301670679959","article-title":"Early damage as measured by the SLICC\/ACR damage index is a predictor of mortality in systemic lupus erythematosus","volume":"10","author":"Rahman","year":"2001","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/art.42375","article-title":"Incidence, Prevalence, and mortality of lupus nephritis: a population-based study over four decades using the Lupus Midwest Network","volume":"75","author":"Hocaoglu","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"10.1016\/j.mayocp.2026.05.009_bib61","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib62","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.rdc.2020.07.004","article-title":"Socioeconomic status, health care, and outcomes in systemic lupus erythematosus","volume":"46","author":"DeQuattro","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"issue":"12","key":"10.1016\/j.mayocp.2026.05.009_bib63","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/art.42645","article-title":"Association between severe nonadherence to hydroxychloroquine and systemic lupus erythematosus flares, damage, and mortality in 660 patients from the SLICC inception cohort","volume":"75","author":"Nguyen","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.009_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001317","article-title":"Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA","volume":"11","author":"Figueroa-Parra","year":"2024","journal-title":"Lupus Sci Med"},{"issue":"9","key":"10.1016\/j.mayocp.2026.05.009_bib65","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.mayocp.2026.05.009_bib66","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.32190","article-title":"Hydroxychloroquine and cardiovascular events in patients with systemic lupus erythematosus","volume":"7","author":"Grimaldi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.mayocp.2026.05.009_bib67","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/acr.24255","article-title":"Hydroxychloroquine and mortality among patients with systemic lupus erythematosus in the general population","volume":"73","author":"Jorge","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib68","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/acr.24850","article-title":"Hydroxychloroquine use and cardiovascular events among patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"75","author":"Jorge","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.mayocp.2026.05.009_bib69","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.41934","article-title":"American College of Rheumatology white paper on antimalarial cardiac toxicity","volume":"73","author":"Desmarais","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib71","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","article-title":"Treat-to-target in systemic lupus erythematosus: advancing towards its implementation","volume":"18","author":"Parra Sanchez","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2026.05.009_bib72","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.mayocp.2026.05.009_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103773","article-title":"Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force","volume":"24","author":"Piga","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib74","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib75","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jaad.2014.12.025","article-title":"Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature","volume":"72","author":"Chasset","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"10.1016\/j.mayocp.2026.05.009_bib76","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2026.05.009_bib77","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1056\/NEJMoa050817","article-title":"A trial of contraceptive methods in women with systemic lupus erythematosus","volume":"353","author":"Sanchez-Guerrero","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib78","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"issue":"12","key":"10.1016\/j.mayocp.2026.05.009_bib81","article-title":"Renal replacement therapy in lupus nephritis-related end-stage kidney disease: a systematic review and meta-analysis","volume":"7","author":"Kawtharany","year":"2025","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib82","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/M18-1570","article-title":"Renal transplantation and survival among patients with lupus nephritis: a cohort study","volume":"170","author":"Jorge","year":"2019","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1016\/j.mayocp.2026.05.009_bib83","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.3390\/jcm11206016","article-title":"Arthritis in systemic lupus erythematosus: from 2022 International GISEA\/OEG Symposium","volume":"11","author":"Ceccarelli","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/096120339400300310","article-title":"Fibromyalgia syndrome and disease activity in systemic lupus erythematosus","volume":"3","author":"Morand","year":"1994","journal-title":"Lupus"},{"key":"10.1016\/j.mayocp.2026.05.009_bib85","series-title":"Dubois' Lupus Erythematosus and Related Syndromes","first-page":"421","article-title":"Skin disease in cutaneous lupus erythematosus","author":"Chong","year":"2025"},{"issue":"2","key":"10.1016\/j.mayocp.2026.05.009_bib86","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2133.2011.10397.x","article-title":"Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart","volume":"165","author":"Marzano","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib87","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000291","article-title":"Alopecias in lupus erythematosus","volume":"5","author":"Concha","year":"2018","journal-title":"Lupus Sci Med"},{"issue":"8","key":"10.1016\/j.mayocp.2026.05.009_bib88","first-page":"1236","article-title":"S2k guideline: diagnosis and management of cutaneous lupus erythematosus \u2014 part 1: classification, diagnosis, prevention, activity scores","volume":"19","author":"Worm","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib89","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus \u2014 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000221","article-title":"Associates and predictors of pleurisy or pericarditis in SLE","volume":"4","author":"Ryu","year":"2017","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.05.009_bib91","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1177\/0961203315625460","article-title":"Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus","volume":"25","author":"Zhao","year":"2016","journal-title":"Lupus"},{"issue":"25","key":"10.1016\/j.mayocp.2026.05.009_bib92","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.jacc.2025.05.023","article-title":"2025 concise clinical guidance: an ACC expert consensus statement on the diagnosis and management of pericarditis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"86","author":"Wang","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000078","article-title":"Haematological manifestations of lupus","volume":"2","author":"Fayyaz","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.mayocp.2026.05.009_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"Jager","year":"2020","journal-title":"Blood Rev"},{"issue":"23","key":"10.1016\/j.mayocp.2026.05.009_bib95","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib96","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","article-title":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes","volume":"42","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.mayocp.2026.05.009_bib97","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41584-024-01163-z","article-title":"Recent advances in the diagnosis and management of neuropsychiatric lupus","volume":"20","author":"Legge","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.05.009_bib98","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.mayocp.2026.05.009_bib99","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard-2023-224952","article-title":"Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity","volume":"83","author":"Yelnik","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mayocp.2026.05.009_bib101","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of Antiphospholipid Syndrome in the General Population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib102","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib103","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semarthrit.2012.12.002","article-title":"The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review","volume":"43","author":"Schoenfeld","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.mayocp.2026.05.009_bib104","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.05.009_bib105","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41569-024-01045-7","article-title":"Autoimmune diseases and atherosclerotic cardiovascular disease","volume":"21","author":"Porsch","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.mayocp.2026.05.009_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152468","article-title":"Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus","volume":"67","author":"Choi","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.mayocp.2026.05.009_bib107","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib108","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00198-015-3449-7","article-title":"Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"27","author":"Wang","year":"2016","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.mayocp.2026.05.009_bib109","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.20568","article-title":"Osteoporosis and fractures in systemic lupus erythematosus","volume":"64","author":"Bultink","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.mayocp.2026.05.009_bib111","series-title":"Dubois' Lupus Erythematosus and Related Syndromes","first-page":"433","article-title":"The musculoskeletal system and bone metabolism","author":"Sandhu","year":"2025"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib112","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/keaa478","article-title":"The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis","volume":"60","author":"Pego-Reigosa","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib113","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-022-02878-8","article-title":"Utilization of preventive services in a systemic lupus erythematosus population-based cohort: a Lupus Midwest Network (LUMEN) study","volume":"24","author":"Chevet","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib114","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.berh.2013.07.009","article-title":"Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus","volume":"27","author":"Schmeding","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/09612033231219739","article-title":"Referral and evaluation for kidney transplantation among patients with lupus nephritis-related end-stage kidney disease","volume":"33","author":"McPherson","year":"2024","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib116","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/ar4256","article-title":"Update on differences between childhood-onset and adult-onset systemic lupus erythematosus","volume":"15","author":"Mina","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib117","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/annrheumdis-2011-200106","article-title":"A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus","volume":"71","author":"Rygg","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2026.05.009_bib118","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12969-022-00663-0","article-title":"Long-term growth and final adult height outcome in childhood-onset systemic lupus erythematosus","volume":"20","author":"Ponin","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"issue":"8","key":"10.1016\/j.mayocp.2026.05.009_bib119","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/09612033241254170","article-title":"Evaluation of depressive and anxiety symptoms in childhood-onset systemic lupus erythematosus: Frequency, course, and associated risk factors","volume":"33","author":"Neufeld","year":"2024","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.mayocp.2026.05.009_bib120","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.22228","article-title":"Educational and vocational outcomes of adults with childhood- and adult-onset systemic lupus erythematosus: nine years of followup","volume":"66","author":"Lawson","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib121","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/0961203316659546","article-title":"Relationship between health-related quality of life, disease activity and disease damage in a prospective international multicenter cohort of childhood onset systemic lupus erythematosus patients","volume":"26","author":"Moorthy","year":"2017","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib123","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib124","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7326\/M14-2235","article-title":"Predictors of pregnancy outcomes in patients with lupus: a cohort study","volume":"163","author":"Buyon","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.mayocp.2026.05.009_bib125","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.mayocp.2026.05.009_bib126","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2009.119263","article-title":"Evaluation of the risk of anti-SSA\/Ro-SSB\/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine","volume":"69","author":"Izmirly","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.mayocp.2026.05.009_bib127","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1177\/09612033221123251","article-title":"The association of lupus nephritis with adverse pregnancy outcomes among women with lupus in North America","volume":"31","author":"Lucas","year":"2022","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/BOR.0000000000001003","article-title":"Emerging biologic therapies for systemic lupus erythematosus","volume":"36","author":"Kato","year":"2024","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.05.009_bib129","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"Muller","year":"2026","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib130","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/ard-2023-224919","volume":"83","author":"Pitsigavdaki","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2026.05.009_bib131","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/biotech12040062","article-title":"Tracking of systemic lupus erythematosus (SLE) longitudinally using biosensor and patient-reported data: a report on the fully decentralized mobile study to measure and predict lupus disease activity using digital signals \u2014 the OASIS study","volume":"12","author":"Jupe","year":"2023","journal-title":"BioTech (Basel)"},{"key":"10.1016\/j.mayocp.2026.05.009_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/frhs.2025.1503881","article-title":"Telemedicine for under-resourced patients with systemic lupus erythematosus: a qualitative study exploring the views and experiences of patients and their healthcare team","volume":"5","author":"Bowman","year":"2025","journal-title":"Front Health Serv"},{"issue":"11","key":"10.1016\/j.mayocp.2026.05.009_bib133","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1002\/acr.25143","article-title":"Development of American College of Rheumatology quality measures for systemic lupus erythematosus: a modified Delphi process with Rheumatology Informatics System for Effectiveness (RISE) registry data review","volume":"75","author":"Bartels","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626185449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626185449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:46:11Z","timestamp":1792640771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619626185449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":132,"alternative-id":["S0025619626185449"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.05.009","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Lupus Erythematosus: What Every Clinician Needs to Know","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}